Schellens JHM - Search Results

1

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS, Ranson M, Danson S, Calvert H, Plummer R, Morris C, Carvajal RD, Chirieac LR, Schellens JHM, Shapiro GI. Boss DS, et al. Among authors: schellens jhm. Ann Oncol. 2010 Apr;21(4):884-894. doi: 10.1093/annonc/mdp377. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825886 Free PMC article. Clinical Trial.

2

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer.

Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J. Mackean M, et al. J Clin Oncol. 1998 Sep;16(9):2977-85. doi: 10.1200/JCO.1998.16.9.2977. J Clin Oncol. 1998. PMID: 9738566 Clinical Trial.

3

Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Schellens JH, Heinrich B, Lehnert M, Gore ME, Kaye SB, Dombernowsky P, Paridaens R, van Oosterom AT, Verweij J, Loos WJ, Calvert H, Pavlidis N, Cortes-Funes H, Wanders J, Roelvink M, Sessa C, Selinger K, Wissel PS, Gamucci T, Hanauske AR. Schellens JH, et al. Invest New Drugs. 2002 Feb;20(1):83-93. doi: 10.1023/a:1014454821885. Invest New Drugs. 2002. PMID: 12003197 Clinical Trial.

4

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

Crul M, de Klerk GJ, Swart M, van't Veer LJ, de Jong D, Boerrigter L, Palmer PA, Bol CJ, Tan H, de Gast GC, Beijnen JH, Schellens JH. Crul M, et al. J Clin Oncol. 2002 Jun 1;20(11):2726-35. doi: 10.1200/JCO.2002.09.116. J Clin Oncol. 2002. PMID: 12039935 Clinical Trial.

5

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH. Kruijtzer CM, et al. J Clin Oncol. 2002 Jul 1;20(13):2943-50. doi: 10.1200/JCO.2002.12.116. J Clin Oncol. 2002. PMID: 12089223 Clinical Trial.

6

Urinary and fecal excretion of topotecan in patients with malignant solid tumours.

Herben VM, Schoemaker nE, Rosing H, van Zomeren DM, ten Bokkel Huinink WW, Dubbelman R, Hearn S, Schellens JH, Beijnen JH. Herben VM, et al. Cancer Chemother Pharmacol. 2002 Jul;50(1):59-64. doi: 10.1007/s00280-002-0454-2. Epub 2002 Apr 5. Cancer Chemother Pharmacol. 2002. PMID: 12111113 Clinical Trial.

7

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.

Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JH, Beijnen JH, ten Bokkel Huinink WW. Crul M, et al. Eur J Cancer. 2002 Aug;38(12):1615-21. doi: 10.1016/s0959-8049(02)00127-2. Eur J Cancer. 2002. PMID: 12142051 Clinical Trial.

8

Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

Van Kesteren Ch, Mathôt RA, Raymond E, Armand JP, Dittrich Ch, Dumez H, Roché H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JH; Early Clinical Studies Group of the European Organization for Research and Treatment of Cancer. Van Kesteren Ch, et al. J Clin Oncol. 2002 Oct 1;20(19):4065-73. doi: 10.1200/JCO.2002.01.005. J Clin Oncol. 2002. PMID: 12351604

9

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.

Kruijtzer CM, Schellens JH, Mezger J, Scheulen ME, Keilholz U, Beijnen JH, Rosing H, Mathôt RA, Marcus S, van Tinteren H, Baas P. Kruijtzer CM, et al. J Clin Oncol. 2002 Dec 1;20(23):4508-16. doi: 10.1200/JCO.2002.04.058. J Clin Oncol. 2002. PMID: 12454106 Clinical Trial.

10

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.

Kruijtzer CM, Boot H, Beijnen JH, Lochs HL, Parnis FX, Planting AS, Pelgrims JM, Williams R, Mathôt RA, Rosing H, Schot ME, Van Tinteren H, Schellens JH. Kruijtzer CM, et al. Ann Oncol. 2003 Feb;14(2):197-204. doi: 10.1093/annonc/mdg078. Ann Oncol. 2003. PMID: 12562644 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

754 results

Search Page

Filters